Colorectal cancer remains a prevalent and deadly form of cancer. A significant challenge to treating colorectal tumors is the creation of a suppressive tumor immune microenvironment that leads to tumor progression and resistance to immunotherapy.
The U.S. FDA greenlighted Highfield Biopharmaceuticals Co. Ltd.’s IND, paving way for the Chinese immunotherapy firm to begin clinical testing its immunoliposome cancer therapy.
The U.S. FDA greenlighted Highfield Biopharmaceuticals Co. Ltd.’s IND, paving way for the Chinese immunotherapy firm to begin clinical testing its immunoliposome cancer therapy.
C-type lectin receptor is a family of molecules consisting of several proteins that recognize a broad spectrum of ligands, such as immunoreceptor tyrosine-based activation motif (ITAM) and immunoreceptor tyrosine-based inhibitory motif (ITIM), and are known to regulate diverse immunological functions.
Researchers from Washington University presented data from a study that aimed to identify myeloid-derived suppressor cell (MDSC) markers in patients with multiple sclerosis (MS).
Translationally controlled tumor protein (TCTP) is an immunomodulator that initiates development of an inflammatory milieu in the tumor microenvironment, where TCTP regulates high myeloid-derived suppressor cell activity, researchers have reported.
